Ascendiant Capital Markets Increases Atossa Therapeutics (NASDAQ:ATOS) Price Target to $6.50

Atossa Therapeutics (NASDAQ:ATOS) had its target price upped by stock analysts at Ascendiant Capital Markets from $6.25 to $6.50 in a research note issued on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Ascendiant Capital Markets’ target price would suggest a potential upside of 327.63% from the stock’s current price.

ATOS has been the topic of a number of other research reports. StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Atossa Therapeutics in a research report on Thursday, June 20th. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Atossa Therapeutics in a research report on Monday, August 12th.

Atossa Therapeutics Stock Up 4.1 %

NASDAQ:ATOS traded up $0.06 on Wednesday, reaching $1.52. 755,577 shares of the company’s stock traded hands, compared to its average volume of 1,213,870. The firm has a market cap of $191.16 million, a PE ratio of -6.08 and a beta of 1.20. Atossa Therapeutics has a 12 month low of $0.62 and a 12 month high of $2.31. The stock has a 50-day simple moving average of $1.32 and a 200-day simple moving average of $1.39.

Atossa Therapeutics (NASDAQ:ATOS) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, equities analysts anticipate that Atossa Therapeutics will post -0.22 earnings per share for the current year.

Institutional Investors Weigh In On Atossa Therapeutics

A number of institutional investors have recently modified their holdings of the business. Cetera Advisors LLC purchased a new position in Atossa Therapeutics in the first quarter valued at about $72,000. Virtu Financial LLC acquired a new position in Atossa Therapeutics in the first quarter valued at approximately $151,000. Vanguard Group Inc. lifted its holdings in shares of Atossa Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after purchasing an additional 78,269 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Atossa Therapeutics by 11.9% during the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock worth $1,846,000 after acquiring an additional 164,540 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Atossa Therapeutics during the 2nd quarter worth approximately $29,000. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.